Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Solid cancers comprise a large number of new cases and deaths from cancer each year
globally. There are a number of strategies for addressing tumors raised from solid organs …

Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer
genotyping and longitudinal disease monitoring. However, owing to past emphasis on …

Liquid biopsy, a minimally invasive approach, is a highly powerful clinical tool for the real‐
time follow‐up of cancer and overcomes many limitations of tissue biopsies. Epigenetic …

The development of the sequencing technologies allowed the generation of huge amounts
of molecular data from a single cancer specimen, allowing the clinical oncology to enter the …

Uveal melanoma (UM) is the most common primary intraocular malignancy affecting adults.
Despite successful local treatment of the primary tumour, metastatic disease develops in up …

Genetic intra-tumour heterogeneity fuels clonal evolution, but our understanding of clinically
relevant clonal dynamics remain limited. We investigated spatial and temporal features of …

Purpose: Early diagnosis of cancer is critical for improving patient outcomes, but cancers
may be hard to diagnose if patients present with nonspecific signs and symptoms. We have …

Subclonal heterogeneity and evolution are characteristics of breast cancer that play a
fundamental role in tumour development, progression and resistance to current therapies. In …

Cellular heterogeneity is a major cause of treatment resistance in cancer. Despite recent
advances in single-cell genomic and transcriptomic sequencing, it remains difficult to relate …